News from urologytime.comFollowNews from urologytime.comAll of today’s top news stories from urologytime.com. Get the full analysis behind how media bias impacts breaking news.Overall, we’ve indexed 318 stories from urologytime.com over the past 3 months. We’ve assigned a media bias rating of to urologytime.com. You can read more about our methodology here. urologytime.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow All of today’s top news stories from urologytime.com. Get the full analysis behind how media bias impacts breaking news. Overall, we’ve indexed 318 stories from urologytime.com over the past 3 months. We’ve assigned a media bias rating of to urologytime.com. You can read more about our methodology here. urologytime.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about urologytime.comWhere is urologytime.com located?urologytime.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top urologytime.com NewsMore Patients Opting for Close Monitoring of Early Stage Prostate CancerProstate cancer is the second most commonly diagnosed cancer in men (behind skin cancer), with varying levels of aggressiveness. It’s also the second leading cause of cancer death, behind only lung cancer. A new study led by Yale Cancer Center researchers at Yale School Medicine found a substantial increase in the adoption of active surveillance (AS) and watchful waiting (WW) treatment strategies over the past decade — an encouraging trend for meSee the StoryCapivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPCData from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.See the StoryUnited States · United StatesFDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPCThe FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.See the StoryLatest News StoriesTopics Most Covered by urologytime.comArtificial IntelligenceUTICancerHealthEducationArtificial IntelligenceUTICancerSources Covering Similar Topicsonclive.comtargetedonc.comcancernetwork.comPharmacy Timespipelinereviewonclive.comtargetedonc.comcancernetwork.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
